L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics (SANDIA)
Primary Purpose
Asthma
Status
Completed
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
L-citrulline
Sponsored by

About this trial
This is an interventional treatment trial for Asthma focused on measuring L-citrulline, ADMA, Asthma, Obesity
Eligibility Criteria
Inclusion Criteria:
- Male and female patients, 18-75 yrs old, from all racial/ethnic backgrounds
- Diagnosis of asthma for >1 yr
- BMI ≥ 30
- Baseline pre-bronchodilator FEV1 between 60 and 90% predicted with a 12% or greater bronchodilator response to 4 puffs of albuterol
- Smoking history <20 pack years and no smoking in the last year
- Able to identify age of asthma onset
Exclusion Criteria:
- Respiratory tract infection within the last 4 weeks;
- Oral CS burst within the last 4 weeks or regular systemic CS use
- Hospitalization within the last 3 months
- ER visit within the 4 weeks
- Significant or uncontrolled concomitant medical illness including (but not limited to) heart disease, cancer, diabetes
- Current smoking or within the previous 12 months
- Current use of statins for the past 30 days (Statins lower ADMA levels)
- Pregnancy
- Intolerance or allergy to L-arginine or L-citrulline
- Phosphodiesterase inhibitors
- Taking oral nitrates
Sites / Locations
- Asthma Institute, University of Pittsburgh
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Placebo Comparator
Arm Label
L-citrulline
Placebo
Arm Description
3-gr/day of L-citrulline effervescent powder mix
3 gr of Placebo/day matching L-citrulline effervescent powder
Outcomes
Primary Outcome Measures
Exhaled nitric oxide
Patients will be randomized to 1 week of 3 g of L-citrulline/day vs matching placebo, The outcome is the pre to post intervention change in exhaled NO
Secondary Outcome Measures
Sputum and plasma L-arginine/ADMA levels
This outcome compares the pre to post L-citrulline supplementation changes in sputum and plasma L-arginine/ADMA
Full Information
NCT ID
NCT01715844
First Posted
October 16, 2012
Last Updated
June 29, 2017
Sponsor
University of Pittsburgh
1. Study Identification
Unique Protocol Identification Number
NCT01715844
Brief Title
L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics
Acronym
SANDIA
Official Title
L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics
Study Type
Interventional
2. Study Status
Record Verification Date
June 2017
Overall Recruitment Status
Completed
Study Start Date
September 7, 2013 (Actual)
Primary Completion Date
June 1, 2016 (Actual)
Study Completion Date
June 1, 2017 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Pittsburgh
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
In people who develop asthma after the age of 12 and who are also overweigh, there can be an increased burden of asthma symptoms, more flare-ups, and poorly-controlled asthma when compared to normal weight asthmatics. Certain factors are more abundant in the blood of individuals who are obese. One such factor is derived from the metabolism of an amino acid found in your diet, which is known as L-arginine (Amino acids are most commonly known as the building blocks of proteins, the same as the proteins found in food). This factor is called asymmetric dimethylarginine or ADMA. The balance of L-arginine to ADMA may be important to the health of subjects with asthma. The balance between L-arginine and ADMA plays an important role in producing nitric oxide (NO) in the airways. NO is normally produced in the lung and plays a major role in maintaining airways open and functioning normally. Our research has shown that in subjects with asthma who are overweight and developed asthma later in life, the combination of low L-arginine and high ADMA, may lead to lower NO levels. We are asking participants in this study to take L-citrulline, which is converted to L-arginine by your body, as a supplement for a period of one week. We anticipate that L-citrulline will restore NO levels in the airways, by increasing the ratio of L-arginine to ADMA
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Asthma
Keywords
L-citrulline, ADMA, Asthma, Obesity
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
10 (Actual)
8. Arms, Groups, and Interventions
Arm Title
L-citrulline
Arm Type
Active Comparator
Arm Description
3-gr/day of L-citrulline effervescent powder mix
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
3 gr of Placebo/day matching L-citrulline effervescent powder
Intervention Type
Dietary Supplement
Intervention Name(s)
L-citrulline
Other Intervention Name(s)
L-citrulline 3 gr efervescent powder
Intervention Description
Patients will take 3-gr of L-citrulline/day for 7 days
Primary Outcome Measure Information:
Title
Exhaled nitric oxide
Description
Patients will be randomized to 1 week of 3 g of L-citrulline/day vs matching placebo, The outcome is the pre to post intervention change in exhaled NO
Time Frame
1 week
Secondary Outcome Measure Information:
Title
Sputum and plasma L-arginine/ADMA levels
Description
This outcome compares the pre to post L-citrulline supplementation changes in sputum and plasma L-arginine/ADMA
Time Frame
1 week
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Male and female patients, 18-75 yrs old, from all racial/ethnic backgrounds
Diagnosis of asthma for >1 yr
BMI ≥ 30
Baseline pre-bronchodilator FEV1 between 60 and 90% predicted with a 12% or greater bronchodilator response to 4 puffs of albuterol
Smoking history <20 pack years and no smoking in the last year
Able to identify age of asthma onset
Exclusion Criteria:
Respiratory tract infection within the last 4 weeks;
Oral CS burst within the last 4 weeks or regular systemic CS use
Hospitalization within the last 3 months
ER visit within the 4 weeks
Significant or uncontrolled concomitant medical illness including (but not limited to) heart disease, cancer, diabetes
Current smoking or within the previous 12 months
Current use of statins for the past 30 days (Statins lower ADMA levels)
Pregnancy
Intolerance or allergy to L-arginine or L-citrulline
Phosphodiesterase inhibitors
Taking oral nitrates
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Fernando Holguin, MD MPH
Organizational Affiliation
University of Pittsburgh
Official's Role
Principal Investigator
Facility Information:
Facility Name
Asthma Institute, University of Pittsburgh
City
Pittsburgh
State/Province
Pennsylvania
ZIP/Postal Code
15213
Country
United States
12. IPD Sharing Statement
Citations:
PubMed Identifier
31714895
Citation
Holguin F, Grasemann H, Sharma S, Winnica D, Wasil K, Smith V, Cruse MH, Perez N, Coleman E, Scialla TJ, Que LG. L-Citrulline increases nitric oxide and improves control in obese asthmatics. JCI Insight. 2019 Dec 19;4(24):e131733. doi: 10.1172/jci.insight.131733.
Results Reference
derived
Learn more about this trial
L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics
We'll reach out to this number within 24 hrs